Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial. Merck has ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

KEYNOTE-689 trial showed significant improvement in event-free survival for stage 3 or 4A resected head and neck squamous cell carcinoma with Keytruda. Keytruda regimen included neoadjuvant therapy, ...

Merck (NYSE:MRK) announced Tuesday that its Phase 3 KEYNOTE-689, designed to evaluate its anti-PD-1 therapy Keytruda as a ...

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 12 ... have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or ...

An outspoken Columbia University professor, who has accused the school of being a hotbed of antisemitism, has been temporarily banned from its campus. Columbia said it isn’t letting Shai Davidai ...

Merck stock fell early Monday after a rival pharmaceutical company said its cancer drug beat Merck’s Keytruda in a ...

Columbia reported on Sept. 27 an investment return of 11.5 percent on its endowment for the fiscal year of 2024—putting the University on track to outperform peer institutions in investment returns.

By Vimal Patel and Sharon Otterman Columbia University has temporarily barred a vocal pro-Israel professor from campus, saying he repeatedly harassed and intimidated the school’s employees.